The survival analysis formed by GEPIA database indicated that reduction of CDH23 represented poor overall survival (OS) (Figure 1E, p<0.01), as well as poor disease-free survival (DFS) in DLBCL patients (Figure 1F, p<0.01). This evidence concerns the gene CDH23 and diffuse large B-cell lymphoma.